Metastasis-Associated in Colon Cancer 1 Is a Novel Survival-Related Biomarker for Human Patients with Renal Pelvis Carcinoma

Abstract

Metastasis-associated in colon cancer 1 (MACC1) has recently been identified as a novel independent prognostic indicator for metastasis occurrence, overall survival and cancer-free survival for patients with colon cancer and other solid tumors. In this study, we investigated the role of MACC1 in the development and progression of renal pelvis carcinoma, a form of upper tract urothelial carcinomas. MACC1 protein has been found in the cytoplasm as well as in the nucleus of the transitional epithelial cells of the normal renal pelvis in immunohistochemical (IHC) assays. Quantitative IHC examinations revealed that MACC1 abnormal abundance in cancerous tissues might represent a biological indicator clinically suggestive of tumor malignancy in the renal pelvis. Furthermore, investigation of the association of MACC1 protein levels with clinicopathological parameters in this study has suggested a correlation of MACC1 expression with tumor-node-metastasis stage and histopathological grade of patients with renal pelvis carcinoma, with elevated MACC1 protein levels frequently associated with higher aggressiveness of the disease. Moreover, both disease-free survival and overall survival for the patients in the high MACC1 expression group were significantly lower than those in the low expression group. Multivariate analysis with a Cox proportional-hazards model suggested that MACC1 is indeed an independent prognostic indicator of overall survival and cancer-free survival for patients with renal pelvis carcinoma. Thus, MACC1 may represent a promising prognostic biomarker candidate, as well as a potential therapeutic target for this disease.

Metastasis-associated in colon cancer-1 and aldehyde dehydrogenase 1 are metastatic and prognostic biomarker for non-small cell lung cancer

“…MACC1 is considered an independent factor for prognosis and metastasis in colorectal cancer [3, 7]. Accumulating studies suggest that it could also be a prognostic and metastatic factor for other cancers, such as breast cancer [8], gastric carcinoma [9], hepatocellular carcinoma [10], renal pelvis carcinoma [11], malignant glioma [12], cervical carcinoma [13], and lung cancer [5]. …”

Heterogeneity analysis of Metastasis Associated in Colon Cancer 1 (MACC1) for survival prognosis of colorectal cancer patients: a retrospective cohort study

“…In CRC patients, MACC1 is a tumor stage-independent predictor for metastasis and survival, and allows early identification of high-risk cases [ 4 - 6 ]. Importantly, MACC1 has also been identified as a valuable biomarker in carcinomas of the gastrointestinal tract such as gastric [ 7 ], esophagus [ 8 ], pancreatic [ 9 ] and hepatobiliary [ 10 - 12 ] as well as in carcinomas of the lung [ 13 - 15 ], ovaries [ 16 ], breast [ 17 , 18 ], upper urothelial tract [ 19 ], nasopharynx [ 20 ], malignant glioma [ 21 , 22 ] and osteosarcomas [ 23 ]. Remarkably, MACC1 levels consistently correlated with tumor progression, development of metastasis and patient survival in this broad range of solid tumor types, making MACC1 a decisive driver for disease progression (reviewed in [ 24 ]).…”

Peer Review #2 of "Kill two birds with one stone: making multi-transgenic pre-diabetes mouse models through insulin resistance and pancreatic apoptosis pathogenesis (v0.1)"

“…6C, Tg ControlD group< Nc ControlD, ** p<0.01), and HFHSD resulted in enlargement of the islet area (as a result, Tg HFHSD insulin intensity was low) (Fig. 6B) (Hu 2014;Ruan et al 2016). The AOD of pancreatic IAPP expression shows the IAPP average accumulation density of the animals in the four groups (the corresponding left panel shows the IAPP immunohistochemistry) (Fig.…”

“…The immunohistochemistry was tested for islets, and insulin secretion was assessed using an antibody to pancreatic insulin (Abcam, ab63820). The AOD of pancreatic insulin expression was calculated as the IOD (integral optical density) sum/Area sum (Hu 2014;Ruan et al 2016). To detect amylin deposition within islets in the pancreas, immunohistochemical analysis of IAPP was performed using an anti-amylin antibody (Abcam ab115766).…”